title: Pilot study and protocol of the Canadian Trial of Atrial Fibrillation (CTAF).
abstract: Antiarrhythmic drug prophylaxis in patients with atrial fibrillation (AF) is associated with a high incidence of arrhythmic recurrence. Uncontrolled studies have suggested that low-dose amiodarone may be superior in terms of efficacy to other antiarrhythmic drugs while having an acceptable side effect profile. The Canadian Trial of Atrial Fibrillation (CTAF) is a 25-center study sponsored by the Medical Research Council of Canada to determine the best treatment strategy to maintain sinus rhythm in patients with persistent or paroxysmal AF. Recruitment began in November 1996 and will continue for 1.5 years. Patients are randomized to receive either low-dose amiodarone or conventional antiarrhythmic drug therapy. Patients assigned to the amiodarone group will receive an oral loading regimen of 10 mg/kg/day during a minimum 14-day period. Patients assigned to conventional antiarrhythmic therapy will receive 1 of 2 agents commonly used in AF prophylaxis: sotalol or propafenone. Drug selection and loading, and electrical cardioversion, if necessary, will be performed within 21 days of randomization. The long-term maintenance dose of amiodarone is 200 mg/day. We have planned a minimum follow-up period of 1 year. The primary end point is the time to the first relapse of AF. Data will be analyzed on an intention-to-treat basis. Secondary outcomes are medication toxicity, mortality, major clinical events, costs of each approach, and quality of life. For the purpose of sample size calculations, it is anticipated that recurrence of AF at 1 year will occur in 50% of patients on conventional treatment compared with 35% in those receiving amiodarone. In order to have an 80% power and a 2-tailed type I error of 0.05, assuming a 15% loss to follow-up rate, a total sample size of 400 patients will be required. A pilot study done at the Montreal Heart Institute has shown that the research protocol is feasible.
authors.affiliation: Department of Medicine, Montreal Heart Institute, University of Montreal, Quebec, Canada.
authors.forename: D
authors.initials: D
authors.lastname: Roy
authors.forename: M
authors.initials: M
authors.lastname: Talajic
authors.forename: B
authors.initials: B
authors.lastname: Thibault
authors.forename: M
authors.initials: M
authors.lastname: Dubuc
authors.forename: S
authors.initials: S
authors.lastname: Nattel
authors.forename: M J
authors.initials: MJ
authors.lastname: Eisenberg
authors.forename: A
authors.initials: A
authors.lastname: Ciampi
mesh_terms: D000638:Amiodarone / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000401:mortality; D002170:Canada; D002985:Clinical Protocols; D005240:Feasibility Studies; D005500:Follow-Up Studies; D006801:Humans; D015337:Multicenter Studies as Topic; D010865:Pilot Projects; D016032:Randomized Controlled Trials as Topic
chemical_list: D000889:Anti-Arrhythmia Agents; D000638:Amiodarone